Health and Lifestyle Research Unit, Queen Mary University of London, London, UK.
Faculty of Life Sciences and Medicine, King's College London, London, UK.
Addiction. 2020 Jun;115(6):1141-1148. doi: 10.1111/add.14936. Epub 2020 Jan 29.
To assess the pharmacokinetic (PK) profile of, and users' reactions to, Juul (59 mg nicotine/ml) as an indication of its therapeutic and dependence potential.
Cross-over, within-subjects study in which participants attended after overnight abstinence on separate sessions and smoked a cigarette or used Juul or eight other types of e-cigarettes (EC) ad libitum for 5 minutes. The Juul product used was the version available in the United States that has more nicotine in the e-liquid than the one available in the European Union.
Laboratory setting in the United Kingdom.
Twenty dual users (smokers who also vape) provided data on Juul and cigarettes, with eight also providing data on other EC products.
At each session, number of puffs taken was counted during the 5-minute product use period and blood samples were taken at baseline and at 2, 4, 6, 8, 10 and 30 minutes after starting smoking/vaping and analysed for nicotine. Participants also monitored their urges to smoke and rated the products on a range of characteristics.
Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (C ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (T ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively]. Compared with other EC products, Juul had shorter T [4 minutes, (IQR = 2.5-4.0) versus 6.3 minutes, (IQR = 4.7 - 8.1), P = 0.012] and higher C (28.9 (SD = 15.6) versus 10.6 (SD = 5.5), P = 0.013) despite a lower number of puffs (12.5 (SD = 4.2) versus 17.0 (SD = 4.2), P = 0.084). Compared with other e-cigarette products, it also provided faster reduction of urges to smoke and obtained more favourable subjective ratings.
Juul's PK profile and user ratings suggest that it could be more effective than other EC products in helping smokers to quit smoking, but it may also have a higher potential to generate regular use in non-smokers.
评估 Juul(59 毫克尼古丁/毫升)的药代动力学(PK)特征和使用者反应,以表明其治疗和依赖潜力。
在不同的会议上,参与者在经过一夜的禁欲后进行交叉、个体内研究,并在 5 分钟内自由吸烟或使用 Juul 或其他八种电子烟(EC)。使用的 Juul 产品是美国版,其电子烟液中的尼古丁含量高于欧盟版。
英国的实验室环境。
20 名双重使用者(吸烟同时也使用电子烟者)提供了关于 Juul 和香烟的数据,其中 8 名还提供了关于其他 EC 产品的数据。
在每次会议中,在 5 分钟的产品使用期间,记录吸烟或吸电子烟的口数,并在开始吸烟/吸电子烟后 2、4、6、8、10 和 30 分钟采集血样,并分析尼古丁含量。参与者还监测他们的吸烟欲望,并对产品的一系列特性进行评分。
Juul 的 PK 特征与香烟的 PK 特征非常相似[最大浓度(C)=20.4 与 19.2 纳克/毫升;达到最大浓度的时间(T)=4 与 6 分钟;曲线下面积(AUC):307.9 与 312.6,分别]。与其他 EC 产品相比,Juul 的 T 更短[4 分钟(IQR=2.5-4.0)与 6.3 分钟(IQR=4.7-8.1),P=0.012],C 更高[28.9(SD=15.6)与 10.6(SD=5.5),P=0.013],尽管吸烟口数较少[12.5(SD=4.2)与 17.0(SD=4.2),P=0.084]。与其他电子烟产品相比,它还能更快地减少吸烟欲望,并获得更有利的主观评价。
Juul 的 PK 特征和使用者评价表明,它在帮助吸烟者戒烟方面可能比其他 EC 产品更有效,但它也可能有更高的潜力在非吸烟者中产生常规使用。